GenSight Biologics announces that efficacy and safety data from patients with Leber Hereditary Optic Neuropathy carrying the ND4 mutation treated with lenadogene nolparvovec through early access programs, were presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society.
